Monopar Therapeutics Inc

-0.05 (-0.99%)
Earnings Announcements

Monopar Therapeutics Reports Q2 Results

Published: 08/12/2021 12:18 GMT
Monopar Therapeutics Inc (MNPR) - Q2 Loss per Share $0.17.
Q2 Earnings per Share Estimate $-0.19 -- Refinitiv Ibes Data (analyst estimates).
Monopar Therapeutics - Anticipates Current Cash & Cash Equivalents Will Fund Co's Major Programs at Least Through Sept 2022.
Monopar - Plans to Raise Additional Funds And/or Engage Partner Within Next 12 Months to Complete Voice Program, Continue Camsirubicin Development Beyond Phase 1b Trial.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.